News

Under the agreement with the University of Massachusetts at Amherst (UMA), BioVeris acquired a first option for exclusive rights to commercialize products for possible use in the prevention,

At-risk patients include neonates, patients with indwelling catheters and patients undergoing certain types of surgery. The phase I study will evaluate safety and immune response of the vaccine

Under the terms of the proposed acquisition, Chromos will issue approximately 20.1 million common shares as consideration to Targeted Molecules Corporation (TMC) shareholders During the acquisition process and

If licensed, Fluarix will be used for the active immunization of adults against influenza disease caused by influenza virus types A and B contained in the vaccine. Fluarix

The National Institutes of Health (NIH) license covers a DNA plasmid developed by scientists from the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC).

In the study, children use a nebulizer to inhale cisplatin, a standard cancer drug that has been specially encapsulated in protective fatty protein bubbles. As it the drug

In October 2004, the FDA placed the TNFerade clinical program on hold after blood clots were observed in patients with esophageal cancer in a separate phase II trial.

The new drug application (NDA) contains the largest database ever assembled in a regulatory filing for pulmonary arterial hypertension (PAH), with approximately 900 PAH patients receiving Thelin (sitaxsentan)

Alnylam will apply RNAi technology to the discovery of short interfering RNAs (siRNAs), the active molecules of RNA interference (RNAi), that target key flu genes required for virus